Consensus Sutro Biopharma, Inc.

Stocks

STRO

US8693672011

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-31 EDT			5-day change	1st Jan Change
24.17 ^USD	-2.62%		+5.64%	+108.90%

06-29	Sutro Biopharma, Inc.(NasdaqGM:STRO) added to Russell Small Cap Comp Growth Benchmark	CI
06-29	Sutro Biopharma, Inc.(NasdaqGM:STRO) added to Russell 2500 Growth Benchmark	CI

Evolution of the Average Target: Sutro Biopharma, Inc.

Evolution of the Target Price: Sutro Biopharma, Inc.

Changes in Analyst Recommendations: Sutro Biopharma, Inc.

0bfdd009bbc279a33d6d7e63.FzG086hqcb5JNOC0BokrlWGadpC2K-_MV97EKYtUCag.Ll6NlZsFC8wAAbfNS7Bt7TLcE6jQH9mCP6izEcc8beUvaPuc_AIn_B9Q0A~ccb3854bc0454279dea63145958a9b13

Analysts' recommendations: Sutro Biopharma, Inc.

05-28	Barclays Initiates Sutro Biopharma at Overweight With $56 Price Target	MT
05-15	Sutro Biopharma Shares Rise After Q1 Loss Narrows	MT
05-15	Wedbush Upgrades Sutro Biopharma to Outperform From Neutral, Boosts Price Target to $60 From $22	MT
04-30	Mizuho Initiates Sutro Biopharma at Outperform With $50 Price Target	MT
04-07	Leerink Partners Initiates Sutro Biopharma at Outperform With $38 Price Target	MT
03-25	Deutsche Bank Adjusts Sutro Biopharma Price Target to $55 From $51, Maintains Buy Rating	MT
03-24	Wells Fargo Upgrades Sutro Biopharma to Overweight From Equal Weight, Adjusts PT to $27 From $8	MT
03-24	HC Wainwright Upgrades Sutro Biopharma to Buy From Neutral, Adjusts PT to $28 From $10	MT
03-24	Wedbush Raises Price Target on Sutro Biopharma to $22 From $10, Keeps Neutral Rating	MT
12-17	Deutsche Bank Boosts Price Target on Sutro Biopharma to $51 From $5, Keeps Buy Rating	MT
25-06-16	Piper Sandler Upgrades Sutro Biopharma to Overweight From Neutral, $2 Price Target	MT
25-03-17	HC Wainwright Downgrades Sutro Biopharma to Neutral From Buy, Price Target is $2	MT
25-03-17	Oppenheimer Downgrades Sutro Biopharma to Market Perform From Outperform	MT
25-03-17	Deutsche Bank Adjusts Sutro Biopharma Price Target to $5 From $10, Maintains Buy Rating	MT
25-03-14	Piper Sandler Downgrades Sutro Biopharma to Neutral From Overweight, Adjusts PT to $2 From $8	MT
25-03-14	Wedbush Downgrades Sutro Biopharma to Neutral From Outperform, Adjusts Price Target to $2 From $8	MT
25-03-14	Truist Removes $15 Price Target From Sutro Biopharma, Keeps Buy Rating	MT
24-08-16	Truist Securities Adjusts Price Target on Sutro Biopharma to $15 From $18, Maintains Buy Rating	MT
24-05-08	BofA Securities Starts Sutro Biopharma With Buy Rating	MT
24-04-03	Piper Sandler Trims Price Target on Sutro Biopharma to $11 From $12, Maintains Overweight Rating	MT
24-04-03	Truist Securities Adjusts Price Target on Sutro Biopharma to $18 From $25, Keeps Buy Rating	MT
24-03-26	Wedbush Adjusts Sutro Biopharma's Price Target to $8 From $12, Maintains Outperform Rating	MT
23-11-15	Piper Sandler Adjusts Price Target on Sutro Biopharma to $12 From $18, Maintains Overweight Rating	MT
23-10-06	Oppenheimer Initiates Coverage on Sutro Biopharma With Outperform Rating, $10 Price Target	MT
23-08-11	Wedbush Cuts Sutro Biopharma's PT to $12 From $20, Pushes Back Estimated Launch of STRO-002, Adjusts Capital Raise Assumptions; Keeps Outperform Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	SUTRO BIOPHARMA, INC.					+97.56%
	WUXI APPTEC CO., LTD.					+17.16%
	ARGENX SE					+20.43%
	BIONTECH SE					+34.66%
	INSMED INCORPORATED					+98.97%
	WUXI BIOLOGICS (CAYMAN) INC.					+21.54%
	GENMAB A/S					+28.71%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+17.22%
	PHARMAESSENTIA CORPORATION					+1.26%
	EXELIXIS, INC.					-1.82%
	Average					+33.57%
	Weighted average by Cap.					+26.47%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

24.17USD

Average target price

47.75USD

Spread / Average Target

+97.56%

High Price Target

61.00USD

Spread / Highest target

+152.38%

Low Price Target

10.00USD

Spread / Lowest Target

-58.63%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Barclays
Wedbush
Mizuho Securities
Leerink Partners
Deutsche Bank Securities
HC Wainwright
Wells Fargo Securities
Piper Sandler
Oppenheimer
Truist Securities
BofA Securities
JMP Securities
Berenberg Bank